Clinical Decision-Making
HbA1c, HOMA-IR and Insulin Calculators: Three Different Questions, Three Safety Checks
Editorial record
This source-linked educational article has been updated through AI-assisted evidence checks and editorial review. Verify information against current guidance and local protocols before applying it to patient care.
Citation methodologyHbA1c-derived estimated average glucose, HOMA-IR and an insulin calculator do not form an automatic treatment pathway. They address average glycaemia, a model of fasting physiology, and treatment arithmetic respectively. Confusing those purposes can produce a precise-looking but unsafe conclusion.
HbA1c and eAG: An Average Is Not a Glucose Profile
The ADAG primary study related HbA1c to average glucose over the preceding three months in 507 participants. Its commonly used regression is:
eAG (mg/dL) = 28.7 * HbA1c (%) - 46.7
The corresponding published equation is:
eAG (mmol/L) = 1.59 * HbA1c (%) - 2.59
Enter HbA1c as a percentage, not an IFCC result in mmol/mol. These equations estimate an average; they do not calculate the fasting glucose, prove that glucose stayed near that average or describe hypoglycaemia frequency.
The ADA 2026 glycaemic-goals guidance supports combining HbA1c and/or CGM measures and individualising goals. An HbA1c below 7% (53 mmol/mol) is appropriate for many nonpregnant adults, but it is not a universal target irrespective of hypoglycaemia, frailty or treatment burden.
Check Whether HbA1c Is Interpretable
The NGSP interference resource distinguishes assay interference from altered red-cell survival. Haemoglobin variants can affect particular methods. Shortened red-cell survival, such as in haemolysis, can lower HbA1c independently of glucose; significant iron-deficiency anaemia can raise it. The direction is not adequately captured by saying "all anaemia lowers HbA1c".
When HbA1c disagrees with measured glucose, investigate the discrepancy with the laboratory and clinical team. Do not use the eAG conversion to make an unreliable HbA1c seem more reliable. Glucose monitoring or a suitable alternative marker may be needed; alternative markers also have limitations.
A Discordant Pair Needs a Reconciliation Note
When HbA1c-derived estimated average glucose and a glucose report disagree, first ask whether the reports describe comparable information. Converting HbA1c into glucose units does not turn it into a direct glucose measurement. Averaging the converted number with a meter or sensor average can produce a third number without explaining either of the first two.
The ADAG relationship and HbA1c interpretation limits described above remain relevant. Here the additional question is whether the observation windows and data coverage allow a meaningful comparison at all.
Fictional Report-Comparison Exercise
A fictional adult brings two reports to a routine review. Laboratory HbA1c is 7.4% (approximately 57 mmol/mol) using the NGSP/IFCC relationship. A glucose-monitoring summary reports a mean of 7.2 mmol/L over its most recent 14 calendar days, but the handover does not include the device's data-completeness report. This exercise does not address whether the person is acutely unwell; symptoms or clinical concern require assessment independently of this comparison. No treatment failure or assay interference is diagnosed.
Using the site's implemented ADAG convention:
28.7 * 7.4 - 46.7 = 165.68 mg/dL
165.68 / 18.0182 = 9.1951 mmol/L, approximately 9.2 mmol/L.
It is possible to compute (9.1951 + 7.2) / 2 = 8.1976 mmol/L. But that number is not a validated combined estimate. The two inputs have different origins, time coverage and uncertainty; equal weighting is an invented assumption. The arithmetic is shown to expose the mistake, not to recommend the average.
Nor does subtracting one number from the other identify a cause. The difference of approximately 2.0 mmol/L is descriptive. It cannot distinguish a recent biological change from incomplete monitoring, measurement problems or an HbA1c interpretation issue. No such cause is diagnosed in this example.
Build a Short Report Provenance Record
Begin with the original laboratory result: collection date, HbA1c unit, laboratory identity and any accompanying comments. Ask for the assay method if a method-dependent interference is being investigated. Keep that request linked to the actual report rather than attaching a generic list of possible interferences as though one had been confirmed.
Next describe the glucose record: device or sampling method, start and end dates, available coverage and the circumstances in which measurements were collected. A selected set of readings should not be labelled a complete profile. If the completeness report is absent, say so and obtain it through the usual clinical process.
Finally, create a brief chronology of relevant changes already known to the treating team. Record when they occurred relative to each report. Do not infer medication adherence, dietary behaviour or a red-cell disorder solely from discordance. A neutral question is more useful than a premature explanation.
For this fictional pair, a compact reconciliation log would contain three unresolved entries: whether the 14-day window overlaps the period preceding the HbA1c collection; how much of that window actually contains glucose data; and whether the two reports were linked to the correct person and dates. None is answered by converting the units. Keep the original reports attached to the log so that a later clarification does not overwrite the evidence available at the first review.
State What Remains Unresolved
For the fictional pair, an appropriate documentation conclusion is: "HbA1c-derived eAG and the recent recorded glucose mean differ. The comparison uses different observation periods, and glucose coverage has not yet been confirmed. Clinical and laboratory reconciliation remains outstanding." That conclusion preserves the finding without asserting a cause or prescribing a response.
Use the Converter Once, for the Right Question
The A1C calculator and eAG calculator use the same conversion component. Agreement between these two pages is not independent confirmation of glucose exposure. Neither calculates a sensor mean or repairs an uninterpretable HbA1c.
Complete the reconciliation before attaching diagnostic meaning to the difference. The treating team should interpret the original reports, symptoms and monitoring pattern, including clinically important low readings, rather than allowing an invented blended average to conceal the issue. This addition proposes no glucose target or treatment change.
Fictional Interpretation Task: The Average Conceals Lows
A fictional adult using insulin has HbA1c 8.0%. The eAG calculation gives:
28.7 * 8.0 - 46.7 = 182.9 mg/dL
The mmol/L equation gives approximately 10.1 mmol/L; converting the rounded mg/dL estimate gives approximately 10.2 mmol/L. This small rounding difference is not clinically meaningful.
Their glucose records also show overnight readings of 3.2 mmol/L (about 58 mg/dL) and postmeal readings of 16.0 mmol/L (about 288 mg/dL). These are fictional observations, not a dosing example. Increasing every insulin dose because the average is high would ignore the overnight lows. The ADA 2026 guidance identifies glucose below 3.9 mmol/L (70 mg/dL) as clinically important and emphasises assessment of hypoglycaemia risk.
The next task is to review timing, symptoms, meals, activity and the actual insulin regimen with the treating team. This article does not specify a dose adjustment or replace a hypoglycaemia treatment plan.
HOMA-IR: State the Model and the Units
The Oxford HOMA group's FAQ explains that HOMA1's simple equations approximate a fasting steady-state model. HOMA2 is an iterative computer model, not another name for the same multiplication. Oxford explicitly states that assay differences prevent a universal normal/abnormal threshold. Do not interpret a difference between results from different assays as necessarily a biological change.
For HOMA1-IR, the familiar approximation uses fasting glucose in mmol/L, insulin in microIU/mL, and division by 22.5. With glucose in mg/dL, the equivalent divisor is 405. MicroIU/mL is numerically equivalent to mIU/L; insulin reported in pmol/L is not numerically interchangeable.
For a separate fictional fasting sample, glucose 5.4 mmol/L and insulin 12 microIU/mL give **5.4 12 / 22.5 = 2.88. Using glucose 97.2 mg/dL gives 97.2 12 / 405 = 2.88**. This checks arithmetic, not a diagnosis or a treatment indication.
Do not use 2.88 to choose a medicine, diagnose insulin deficiency or decide whether insulin can be withheld. Nonfasting samples and exogenous insulin undermine ordinary fasting-insulin interpretation; the HOMA developers' methodological discussion describes these limitations. HOMA is not a substitute for formal diabetes assessment.
Insulin Arithmetic Needs an Existing Clinical Plan
Before using a dosing tool, establish the diabetes type, care setting, intended insulin and strength, current doses, recent glucose pattern, kidney function, food intake and active insulin from recent doses. The ADA 2026 pharmacological guidance emphasises individualised treatment and hypoglycaemia risk; it does not make HOMA-IR a dose selector.
Check the output units. A carbohydrate ratio expressed as grams per unit is not units per gram. Insulin units are not millilitres. A correction-factor estimate does not account for every effect of illness, exercise, meals or active insulin. This article deliberately provides no starting-dose recipe, universal titration table or perioperative adjustment instructions.
Learning Question
Can eAG 183 mg/dL and HOMA1-IR 2.88 identify a safe insulin dose?
No. eAG conceals timing and variability, and HOMA does not prescribe treatment. A clinician needs the glucose pattern and patient-specific treatment context; correct calculator arithmetic is only one check within that assessment.
AI-assisted clinician education. Primary sources checked on 17 October 2026. These examples do not validate the site's calculators or authorise medication changes.
Retrospective educational reading plan: Day 26 of 50, retrospective reading date 2026-09-30. This is a study-sequence label, not a publication date, review date or source-check date. The original first-publication timestamp is retained.